Seroresponse was defined as subjects showing a three-fold/four fo

Seroresponse was defined as subjects showing a three-fold/four fold or more rise in serum IgA anti-rotavirus antibody titres, from baseline, as evaluated 28 days after third dose of the of BRV-TV/Rotateq. The per-protocol (PP) analysis set for study included all subjects who had no protocol deviations. Subjects were excluded from the PP analysis set for the following reasons: subject did not meet all protocol-specified inclusion/exclusion criteria, subject did not receive the vaccine, subject received a vaccine other than the

one that he/she was randomized to receive, any blood sample before or 28 (±3) days after administration of BRV-TV/RotaTeq/Placebo not obtained, subject did not provide a post-dose serology sample in the proper time window. Descriptive statistics such as number (n), mean, median, standard deviation selleck kinase inhibitor and range (minimum, maximum) were used for summarizing the

continuous variables. Frequencies and relative frequencies were computed for categorical data. Concentrations of antibodies were log transformed and Geometric Mean Antibody Concentrations (GMCs) were compared. The proportions of participants who sero-responded were compared www.selleckchem.com/products/AZD6244.html using Fisher’s Exact test. Occurrence rates of adverse reactions were compared using Fisher’s exact tests. Confidence intervals (CIs) for the single proportion were calculated using the exact binomial method (Clopper–Pearson method). The entire study data in the Clinical Data Management Database was analysed by Zifo Technologies, Chennai, India with the SAS software, Version 9.2 or

higher (SAS Institute, Cary, North Carolina, USA). All 20 adult subjects were aged between 30 and 48 years with an average age of approximately 41.8 years. Treatment groups were comparable with regard to demography and baseline characteristics. All subjects completed the 10 days post dose safety follow up and no AEs/SAEs were reported from vaccine or placebo groups. A safety report from this Cohort was submitted to the DCGI and the DSMB. After getting clearance from both bodies, recruitment in the infant cohort was started. A total of 113 subjects were screened and of them 100 (20 each in BRV-TV 105.0 FFU, BRV-TV 105.8 FFU, Histone demethylase BRV-TV 106.4 FFU, RotaTeq and placebo group) were randomized. Of 100 randomized and treated subjects, seven (7.0%) did not complete the study. Five were lost to follow up and two (2) were due to consent withdrawal. During the entire study period, major protocol deviations occurred for three subjects (one each from BRV-TV 105.0 FFU, BRV-TV 106.4 FFU and Placebo) resulting in their removal from the per protocol analysis. These were enrolment deviations, where subjects were recruited out of the protocol window (6–8 weeks). A total of 19 (95.0%) subjects in the BRV-TV 105.0 FFU group, 17 (85%) subjects in the BRV-TV 105.8 FFU group, 19 (95.0%) subjects in the BRV-TV 106.4 FFU group, 19 (95.0%) subjects in the RotaTeq group and 19 (95.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>